Bicycle Therapeutics plc, commonly known as BCYC, is a clinical-stage biotechnology company that pioneers a new class of therapeutics based on its innovative bicyclic peptide technology (Bicycle®️ platform) – a revolution in drug discovery and development. The company has a unique clinical strategy and is dedicated to establishing itself as a leader in the biopharmaceutical industry. It's listed on the NASDAQ and headquartered in Cambridge, United Kingdom but also has a strong presence in the U.S., with operations in Lexington, Massachusetts.
Bicycle Therapeutics exploits the unique properties of bicycles®️ – fully synthetic short peptides constrained to form two loops which stabilize their structural geometry – in designing novel drugs. This technology platform enables the rapid development of ‘bicycles’ that combine the best features of several existing therapeutic modalities, including the specificity of antibodies and the distribution kinetics of small molecules.
The therapeutic sphere of BCYC spans a wide range of diseases, including oncology, cardiovascular disease, respiratory ailments, and other disorders. Their lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) developed in collaboration with the Centre for Drug Development of Cancer Research UK. It has moved into clinical trials and is designed to target tumours that express Membrane Type 1 Matrix Metalloproteinase.
Bicycle Therapeutics is in partnership with various pharmaceutical bigwigs, such as AstraZeneca, to develop new classes of medicines based on their proprietary platform. AstraZeneca works with the company to identify bicyclic peptides or Bicycles that AstraZeneca can develop and commercialize.
Despite being a relatively young company, established in 2009, Bicycle Therapeutics has shown promising growth through its commitment to cutting-edge discovery and a robust business strategy. Through the years, the company has maintained a steady focus on its mission of transforming conventional drug delivery approach and developing innovative therapeutics through its novel technology. The company's multi-disciplinary team of leaders in the industry brings forward a dynamic approach that keeps the company on the trajectory of growth, ensuring it remains at the forefront of biotechnology advancements.